Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis.
dipeptidyl peptidase-4 inhibitor
glucose-dependent insulinotropic polypeptide
meta-analysis
metabolism
randomized controlled trials
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
04
2023
accepted:
24
07
2023
medline:
29
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Glucose-dependent insulinotropic polypeptide (GIP) confers a variety of metabolic benefits in type 2 diabetes mellitus (T2DM). This meta-analysis was conducted to investigate the impact of dipeptidyl peptidase 4 (DPP4) inhibitors on GIP levels in T2DM patients. Medline (PubMed), CENTER (Cochrane Library), and Embase (Ovid) were searched and randomized controlled trials (RCTs) evaluating the impact of DPP4 inhibitors on fasting and postprandial GIP levels were obtained. For postprandial GIP, only studies with the data of GIP changes reported as the total area under the curve (AUC Overall, 14 RCTs with 541 T2DM patients were included. Compared to placebo/no treatment, the use of DPP4 inhibitors significantly increased the fasting GIP level (standard mean difference [SMD]: 0.77, 95% confidence interval [CI]: 0.48-1.05, The use of DPP4 inhibitors effectively increases the fasting and postprandial GIP concentrations in T2DM patients. https://www.crd.york.ac.uk/prospero/, identifier CRD42022356716.
Identifiants
pubmed: 37635974
doi: 10.3389/fendo.2023.1203187
pmc: PMC10450336
doi:
Substances chimiques
Dipeptidyl-Peptidase IV Inhibitors
0
Gastric Inhibitory Polypeptide
59392-49-3
Glucose
IY9XDZ35W2
Types de publication
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1203187Informations de copyright
Copyright © 2023 Chai, Zhang, Carr, Deacon, Zheng, Rajpathak, Chen and Yu.
Déclaration de conflit d'intérêts
SC, RZ, YZ and JC are employees of MSD China; SR is employee of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Endocrinol Metab. 2011 Apr;96(4):945-54
pubmed: 21239518
J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9
pubmed: 16912128
Ann Med Surg (Lond). 2022 Apr 16;77:103633
pubmed: 35637990
Circ J. 2007 Jun;71(6):826-33
pubmed: 17526976
Diabetes Care. 2013 Sep;36(9):2756-62
pubmed: 23579178
Diabetes. 2019 May;68(5):906-917
pubmed: 30626611
J Clin Endocrinol Metab. 2000 Oct;85(10):3575-81
pubmed: 11061504
Clin Chem. 2011 Jun;57(6):849-55
pubmed: 21515744
Diabetes Obes Metab. 2018 Apr;20(4):1029-1033
pubmed: 29095568
Diabetes. 2014 Feb;63(2):663-74
pubmed: 24186866
J Clin Endocrinol Metab. 1973 Nov;37(5):826-8
pubmed: 4749457
Diabetes Obes Metab. 2016 Nov;18(11):1100-1109
pubmed: 27300579
Diabetes. 2014 Mar;63(3):1079-92
pubmed: 24296715
Diabetes Ther. 2012 Nov;3(1):10
pubmed: 22986920
Diabetes. 2016 Aug;65(8):2440-7
pubmed: 27207543
Diabetes. 2022 Oct 1;71(10):2209-2221
pubmed: 35796651
Endocrinology. 2020 Jan 1;161(1):
pubmed: 31782955
Drug Res (Stuttg). 2021 Nov;71(9):477-488
pubmed: 34388848
N Engl J Med. 2021 Aug 5;385(6):503-515
pubmed: 34170647
Endocrinology. 2021 Jul 1;162(7):
pubmed: 33782700
Diabetes Obes Metab. 2018 Apr;20(4):1080-1085
pubmed: 29227575
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Eur J Endocrinol. 2021 May 21;185(1):33-45
pubmed: 33886495
Diabetes Obes Metab. 2017 Dec;19(12):1681-1687
pubmed: 28448688
Diabetes Obes Metab. 2021 Sep;23 Suppl 3:5-29
pubmed: 34310013
Peptides. 2020 Mar;125:170206
pubmed: 31756367
Cardiovasc Diabetol. 2021 Nov 24;20(1):225
pubmed: 34819089
Lancet. 2006 Nov 11;368(9548):1696-705
pubmed: 17098089
Clin Endocrinol (Oxf). 2008 Nov;69(5):737-44
pubmed: 18331607
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Diabetes Res Clin Pract. 2014 Dec;106(3):538-47
pubmed: 25451890
J Clin Endocrinol Metab. 2008 Feb;93(2):459-64
pubmed: 18042650
J Clin Endocrinol Metab. 2009 Jan;94(1):81-8
pubmed: 18957505
Mol Metab. 2016 Dec 31;6(2):226-231
pubmed: 28180064
Diabetes Obes Metab. 2011 Apr;13(4):366-73
pubmed: 21226820
Peptides. 2020 Mar;125:170208
pubmed: 31759125
J Diabetes Investig. 2021 Jul;12(7):1128-1135
pubmed: 33949781
Diabetes Obes Metab. 2018 Aug;20(8):1911-1920
pubmed: 29645341
J Clin Endocrinol Metab. 2012 Aug;97(8):2818-26
pubmed: 22685234
Clin Med Insights Endocrinol Diabetes. 2021 Oct 28;14:11795514211051698
pubmed: 34733107
BMJ. 2021 Mar 29;372:n160
pubmed: 33781993
Diabetes. 2011 Dec;60(12):3103-9
pubmed: 21984584
Peptides. 2020 Mar;125:170196
pubmed: 31706956
Nat Rev Endocrinol. 2020 Nov;16(11):642-653
pubmed: 32929230
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
J Diabetes Investig. 2022 Jul;13(7):1122-1128
pubmed: 35452190